Welcome to our dedicated page for Reliance Global Group news (Ticker: EZRA), a resource for investors and traders seeking the latest updates and insights on Reliance Global Group stock.
Reliance Global Group reports news about its insurance and InsurTech operating foundation, financial results and strategic venture investments. Recurring company updates cover the RELI Exchange platform for independent insurance agencies, agency recruiting and productivity initiatives, and business updates tied to the company's insurance commission-based operations.
News also covers EZRA International Group and Reliance's ownership-driven investments in technology and life sciences. Recent themes include Enquantum's post-quantum cryptography platform, LifeSci Global's healthcare investment mandate, Innervate Radiopharmaceuticals' radiopharmaceutical development work, conference participation and governance or capital-allocation updates tied to the company's strategic ventures model.
Reliance Global Group (NASDAQ: EZRA) appointed Judah Korman as COO, Zack Wilder as CTO, and Mordy Beyman as Executive Vice President, effective June 22, 2026.
The new leadership team will drive a dual AI-focused strategy: an AI-powered insurance agency acquisition roll-up and in-house development of AI-native, digitally distributed insurance products, supported by a newly formed AI engineering team.
Reliance Global Group (Nasdaq: EZRA) announced it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing.
Nasdaq confirmed EZRA’s closing bid price stayed at or above $1.00 for 10 consecutive business days from May 18–June 1, 2026, closing the matter.
Reliance Global Group (Nasdaq: EZRA) provided an update on its post-quantum cybersecurity investment ENQUANTUM, highlighting a technical milestone as urgency around quantum-resilient security rises. ENQUANTUM is developing infrastructure-grade, low-latency post-quantum encryption for critical systems including financial networks, AI workloads and telecommunications.
Reliance points to growing alignment between government policy, enterprise cybersecurity planning and quantum infrastructure investment. It notes recent U.S. Department of Commerce letters of intent for about $2.013 billion in CHIPS Act incentives to support quantum computing and infrastructure, and views the sector as entering an early, multi-billion-dollar cybersecurity upgrade cycle.
Reliance Global Group (Nasdaq: EZRA) reported that its strategic platform investment Enquantum successfully completed a real-world private 5G deployment with a leading Israeli construction company, using 5G-connected smart helmets to enhance worker safety, geolocation, geofencing, and real-time site monitoring.
The project received Israel Innovation Authority approval, officially closing the program after successful implementation and validation. Enquantum’s FPGA-accelerated UPF with advanced CPU offloading delivered secure, low-latency private cellular networking designed for industrial, infrastructure, and smart mobility applications.
Reliance Global Group (Nasdaq: EZRA) approved a 1-for-40 reverse stock split of its common stock to help regain compliance with Nasdaq’s $1.00 minimum bid price rule. The split becomes effective May 15, 2026, with split-adjusted trading starting May 18, 2026, under a new CUSIP.
The reverse split will reduce outstanding shares from about 22.23 million to about 555,764, without changing total shareholder ownership percentages. Proportional adjustments will apply to stock options, warrants, and other awards. VStock Transfer, the transfer agent, will coordinate share exchanges for certificated holders.
Reliance Global Group (NASDAQ: EZRA) reported Q1 2026 results and advanced its Scale51 strategy with targeted technology and life sciences investments.
Highlights include increased Enquantum ownership to ~29%, formation of LifeSci Global and an investment in Innervate Radiopharmaceuticals, cash and restricted cash of ~$3.2M, and a Q1 net loss of ~$1.4M.
Reliance Global Group (NASDAQ: EZRA) will host a conference call on May 7, 2026 at 4:30 PM ET to discuss first quarter 2026 financial results and provide a business update.
Participants can join by phone using access code 943560 or via webcast; replays will be available online through May 7, 2027 and by telephone through May 21, 2026.
Reliance Global Group (Nasdaq: EZRA) launched LifeSci Global on May 5, 2026, a dedicated life sciences platform co-founded with Scott Korman and David Turner as founding operator-partners. LifeSci Global's first platform investment is Innervate Radiopharmaceuticals, focused on PET imaging and a therapeutic initially targeting neuroblastoma.
Innervate's lead asset, 18F-mFBG, targets an estimated neuroblastoma market opportunity of approximately $250 million, with potential expansion into cardiovascular and neurodegenerative indications and possible Priority Review Voucher upside if approved.
Reliance Global Group (NASDAQ: EZRA) completed a strategic investment through its LifeSci Global biotech division in Innervate Radiopharmaceuticals on May 4, 2026.
LifeSci Global agreed to acquire 421,053 shares at $4.75 (~$2.0 million total), with $500,000 funded at closing and staged follow-on funding rights. Innervate’s lead asset is 18F-mFBG for PET imaging in neuroblastoma; initial market opportunity ~$250M, with potential >$1B expansion markets and possible Priority Review Voucher upside. Interested directors recused; certain directors hold equity in LifeSci Global.
Reliance Global Group (Nasdaq: EZRA) increased its equity stake in Enquantum to approximately 29% after Enquantum met defined technical and commercial milestones on April 28, 2026. Reliance expects a pathway to a 51% fully diluted controlling interest if remaining milestones are met.
Enquantum set latency targets for its alpha: 20–80 microseconds for Kyber768 key generation/verification and ~1 microsecond for AEAD processing; AEAD lab testing and full benchmarking are forthcoming.